stockrowKrystal Biotech, Inc.
KRYS Healthcare Biotechnology
Krystal Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $389.1 million, up 33.9% from fiscal 2024.
- Revenue
- +30.2%
- EPS
- −22.3%
- Free cash flow
- +137.8%
Quarter to September 2026, against a year earlier
Follow KRYS
Alert me
Krystal Biotech, Inc. (KRYS) EBITDA
Krystal Biotech, Inc.'s EBITDA for fiscal 2025 was $167.8M, up 131.6% from $72.5M in fiscal 2024. Over the twelve months to 30 September 2026 it was $234.3M. Over the past ten years it has ranged from −$141.8M (fiscal 2022) to $167.8M (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 3 consecutive fiscal years. Krystal Biotech, Inc. ranks 18th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $167.8M | 131.63% |
| FY2024 | $72.5M | — |
| FY2023 | −$103.7M | — |
| FY2022 | −$141.8M | — |
| FY2021 | −$65.5M | — |
| FY2020 | −$31.1M | — |
| FY2019 | −$21.0M | — |
| FY2018 | −$11.8M | — |
| FY2017 | −$4.7M | — |
| FY2016 | −$1.1M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $72.8M | 21.42% |
| Jun 2026 | $60.0M | 8.24% |
| Mar 2026 | $55.4M | 20.38% |
| Dec 2025 | $46.0M | 7.09% |
| 36 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| KRYS Krystal Biotech, Inc. | $234.3M |
| CAI Caris Life Sciences,�Inc. compare | $180.0M |
| TGTX TG Therapeutics, Inc. compare | $136.0M |
| PTGX Protagonist Therapeutics, Inc. compare | $56.4M |
| TWST Twist Bioscience Corporation compare | −$119.6M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$145.8M |
| IBRX ImmunityBio, Inc. compare | −$235.2M |
| SYRE Spyre Therapeutics, Inc. compare | −$250.2M |
| CYTK Cytokinetics, Incorporated compare | −$694.7M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on KRYS
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement